Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Tolerability of MK0533 in Type 2 Diabetes
NCT00543959Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jun 2006
- Primary completion
- Aug 2007
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of MK-0533 in type 2 diabetes mellitus (T2DM) (7 arms), sponsored by Merck & Co. Primary endpoint: Body fluid gain from baseline at 12 weeks. Started Jun 2006; status: terminated.
02
Drugs
MK-0533
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00543959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00543959.